CVM Cel-Sci Corporation

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.

Cel-Sci Corporation

Peers

Recent Analyst Ratings for Cel-Sci Corporation

Cel-Sci Corporation Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Watson Robert Eugene bought $27,800 worth of shares (20,000 units at $1.39), increasing direct ownership by 451% to 24,431 units (SEC Form 4)

Prichep Patricia B bought $11,120 worth of shares (8,000 units at $1.39), increasing direct ownership by 4% to 232,326 units (SEC Form 4)

Kersten Geert R bought $41,700 worth of shares (30,000 units at $1.39), increasing direct ownership by 3% to 1,195,309 units (SEC Form 4)

Cel-Sci Corporation Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Scientific Officer Talor Eyal was granted 10,416 shares, increasing direct ownership by 8% to 135,013 units (SEC Form 4)

Chief Financial Officer Prichep Patricia B was granted 15,432 shares, increasing direct ownership by 6% to 266,230 units (SEC Form 4)

Chief Executive Officer Kersten Geert R was granted 22,786 shares, increasing direct ownership by 2% to 1,240,378 units (SEC Form 4)

CEO Kersten Geert R was granted 12,940 shares, increasing direct ownership by 1% to 1,217,592 units (SEC Form 4)

Chief Scientific Officer Talor Eyal was granted 6,001 shares, increasing direct ownership by 5% to 124,597 units (SEC Form 4)

Chief Financial & Operations Prichep Patricia B was granted 10,727 shares, increasing direct ownership by 4% to 250,798 units (SEC Form 4)

Chief Scientific Officer Talor Eyal was granted 2,264 shares, increasing direct ownership by 2% to 118,596 units (SEC Form 4)

Sr. VP of Operations Prichep Patricia B was granted 4,047 shares, increasing direct ownership by 2% to 240,071 units (SEC Form 4)

Chief Executive Officer Kersten Geert R was granted 4,882 shares, increasing direct ownership by 0.41% to 1,204,652 units (SEC Form 4)

Chief Scientific Officer Talor Eyal was granted 2,068 shares, increasing direct ownership by 2% to 116,332 units (SEC Form 4)